Book Text

1997

REFERENCES

1. American Heart Association: Heart Disease and Stroke Statistics. Dallas, American Heart Association, 2003.

2. Cribier A, Etchaninoff H, Bash A, et al: Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis. First human case description. Circulation 106:3006–3008, 2002.

3. Yusuf S, Sleight P, Pogue J, et al: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. N Engl J Med 342:145–153, 2000.

4. Johnson FB, Sinclair DA, Guarente L: Molecular biology of aging. Cell 96:291–302, 1999.

5. Csiszar A, Ungvari Z, Edwards JG, et al: Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res 90:1159–1166, 2002.

6. van der Loo B, Labugger R, Skepper JN, et al: Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med 192:1731–1744, 2000.

7. Lakatta E: Aging effects on the vasculature in health: Risk factors for cardiovascular disease. Am J Geriatr Cardiol 3:11–17, 1994.

8. Fleg JL, O'Connor F, Gerstenblith G, et al: Impact of age on the cardiovascular response to dynamic upright exercise in healthy men and women. J Appl Physiol 78:890–900, 1995.

9. Fleg JL, Schulman S, O'Connor F, et al: Effects of acute beta-adrenergic receptor blockage on age-associated changes in cardiovascular performance during dynamic exercise. Circulation 90:2333–2341, 1994.

10. Czernin J, Muller P, Chan S, et al: Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation 88:62–69, 1993.

11. Celermajer DS, Sorense KE, Spiegelhalter DJ, et al: Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 24:471–476, 1994.

12. Ignarro LJ, Cirino G, Casini A, Napoli C: Nitric oxide as a signaling molecule in the vascular system: An overview. J Cardiovasc Pharmacol 34:879–886, 1999.

13. Safar ME, Levy BL, Struijker-Boudier H: Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 107:2864–2869, 2003.

14. Lenfant C: Heart research: Celebration and renewal. Circulation 96:3822–3823, 1997.

15. Mosca L: C-reactive protein—to screen or not to screen? N Engl J Med 347:1615–1616, 2002.

16. Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126, 1999.

17. Ross R: The pathogenesis of atherosclerosis—an update. N Engl J Med 314:488–500, 1986.

18. Theroux P, Willerson JT, Armstrong PW: Progress in the treatment of acute coronary syndromes: A 50-year perspective (1950–2000). Circulation 102:IV-2–IV-13, 2000.

19. Alexander RW, Dzau VJ: Vascular biology: The past 50 years. Circulation 102:IV-112–IV-116, 2000.

20. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104:365–372, 2001.

21. Chen M, Capps C, Willerson JT, Zoldhelyi P: E2F-1 regulates nuclear factor-kB activity and cell adhesion potential antiinflammatory activity of the transcription factor E2F-1. Circulation 106:2707–2713, 2002.

22. Dong C, Goldschmidt-Clermont PJ: E2F1—a magic bullet for atherosclerosis? Circulation 106:2640–2641, 2002.

23. Griendling K, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 86:494–501, 2000.

24. Irani K: Oxidant signaling in vascular cell growth, death, and survival: A review of the role of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 87:179–183, 2000.

25. Steinbrecher UP, Parthasarathy S, Leake DS, et al: Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A 81:3883–3887, 1984.

26. Steinberg D, Parthasarathy S, Carew TE, et al: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 321:1196–1197, 1989.

27. Berliner JA, Schwartz DS, Territo MC, et al: Induction of chemotactic cytokines by minimally oxidized LDL. Adv Exp Med Biol 351:13–18, 1993.

28. Fuster V: Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 91:2126–2146, 1994.

29. Fuster V, Fayad ZA, Badimon JJ: Acute coronary syndromes: Biology. Lancet 353(Suppl II):5–9, 1999.

30. Sawyer DB, Loscalzo J: Myocardial hibernation: Restorative or preterminal sleep? Circulation 105:1517–1519, 2002.

31. Hamm CW, Braunwald E: A classification of unstable angina revisited. Circulation 102:118–122, 2000.

32. Braunwald E, Antman EM, Beasley JW, et al: ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation 102:1193–1209, 2000.

33. Serruys PW, Unger F, Sousa JE, et al: Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344:1117–1124, 2001.

34. Kataoka T, Grube E, Honda Y, et al: 7-Hexanoyltaxol-eluting stent for prevention or neointimal growth. Circulation 106:1788–1793, 2002.

35. Babapulle MN, Eisenberg MJ: Coated stents for the prevention of restenosis: Part 1. Circulation 106:2734–2740, 2002.

36. Armstrong PW: Pursuing progress in acute coronary syndromes. Circulation 100:1586–1589, 1999.

37. Quinn MJ, Fitzgerald DJ: Ticlopidine and clopidogrel. Circulation 100:1667–1672, 1999.

38. Dacey LJ, Munoz JJ, Johnson ER, et al: Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg 70:1986–1990, 2000.

39. Mangano DT: Aspirin and mortality from coronary bypass surgery. N Engl J Med 347:1309–1317, 2002.

40. Ambrose JA, Tannenbaum MA, Alexopoulos D: Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 12:56–62, 1988.

41. Little WC, Constantinescu M, Applegate RJ, et al: Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 78(Pt 1):1157–1166, 1988.

42. Fishbein MC, Siegel RJ: How big are coronary arteries that rupture? Circulation 94:2662–2666, 1996.

43. Hening R, Gilpin E, Cowell JW, et al: Prognosis after acute myocardial infarction: A multivariate analysis on mortality and survival. Circulation 59:1124–1136, 1979.

44. ISIS-1: Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction. (First International Study of Infarct Surgery). Lancet 2:57–65, 1986.

45. Held PH, Yusuf S: Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J 14(Suppl F):18–25, 1993.

46. Pepine CJ, Cohn PF, Deedwania PC, et al: Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life: The Atenolol Silent Ischemia Study. Circulation 90:762–768, 1994.

47. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 353:9–13, 1999.

48. Wallace A, Layug B, Tateo I, et al: Prophylactic atenolol reduces postoperative myocardial ischemia. Anesthesiology 88:7–17, 1998.

49. Mangano DT, Layug EG, Wallace A, Tateo I: Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med 335:1713–1720, 1996.

1998

50. Poldermans D, Boersma E, Bax JJ, et al: The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 341:1789–1794, 1999.

51. Merkus D, Kajiya F, Vink H, et al: Prolonged diastolic time fraction protects myocardial perfusion when coronary blood flow is reduced. Circulation 100:75–81, 1999.

52. Garlichs CD, Ahang H, Mugge A, Daniel WG: Beta-blockers reduce the release and synthesis of endothelin-1 in human endothelial cells. Eur J Clin Invest 29:12–16, 1999.

53. Dunzendorfer S, Wiedermann CJ: Modulation of neutrophil migration and superoxide anion release by metoprolol. J Mol Cell Cardiol 32:915–924, 2000.

54. Hijmering ML, Stroes ES, Olijhoek J, et al: Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol 39:683–688, 2002.

55. Kjekshus JK: Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 57:43F–49F, 1986.

56. Effect of verapamil on mortality and major events after acute infarction (the Danish Study Group on Verapamil in Myocardial Infarction). Am J Cardiol 66:779–785, 1990.

57. Wilcox RG, Hampton JR, Banks DC, et al: Trial of early nifedipine in acute myocardial infarction: The TRENT study. BMJ 293:1204–1208, 1986.

58. Freemantle N, Urdahl H, Eastaugh J, Hobbs FD: What is the place of beta-blockade in patients who have experienced a myocardial infarction with preserved left ventricular function? Evidence and (mis)interpretation. Prog Cardiovasc Dis 44:243–250, 2002.

59. Kramer CM, Nicol PD, Rogers WJ, et al: Beta-blockade improves adjacent regional sympathetic innervation during postinfarction remodeling. Am J Physiol 277:H1429–H1434, 1999.

60. Foody JM, Farrell MH, Krumholz HM: Beta-blocker therapy in heart failure: Scientific review. JAMA 287:883–889, 2002.

61. Zaugg M, Schaub MC, Pasch T, Spahn DR: Modulation of beta-adrenergic receptor subtype activities in perioperative medicine: Mechanisms and sites of action. Br J Anaesth 88:101–123, 2002.

62. Booth JV, Spahn DR, McRae RL, et al: Esmolol improves left ventricular function via enhanced beta-adrenergic receptor signaling in a canine model of coronary revascularization. Anesthesiology 97:162–169, 2002.

63. Ferguson TB Jr, Coombs LP, Peterson ED, Society of Thoracic Surgeons National Adult Database: Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. JAMA 287:2221–2227, 2002.

64. Murrell: Lancet 1:80–81, 1879.

65. Sellke FW, Myers PR, Bates JN, Harrison DG: Influence of vessel size on the sensitivity of porcine coronary microvessels to nitroglycerin. Am J Physiol 258:H515–H520, 1990.

66. Harrison DG, Bates JN: The nitrovasodilators. New ideas about old drugs. Circulation 87:1461–1467, 1993.

67. Fink B, Dikalov S, Bassenge E: A new approach for extracellular spin trapping of nitroglycerin-induced superoxide radicals both in vitro and in vivo. Free Radic Biol Med 28:121–128, 2000.

68. Dikalov S, Fink B, Skatchkov M, et al: Formation of reactive oxygen species in various vascular cells during glyceryltrinitrate metabolism. J Cardiovasc Pharmacol Ther 3:51–62, 1998.

69. Boesgaard S, Aldershvile J, Poulsen HE, et al: Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ Res 74:115–120, 1994.

70. Kim D, Rybalkin SD, Pi X, et al: Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 104:2338–2343, 2001.

71. Parker JD, Gori T: Tolerance to the organic nitrates. New ideas, new mechanisms, continued mystery. Circulation 104:2263–2265, 2001.

72. Munzel T, Kurz S, Rajagopalan S, et al: Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 98:1465–1470, 1996.

73. Munzel T, Li H, Mollnau H, et al: Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression. NOS III-mediated superoxide production, and vascular, NO bioavailability. Circ Res 86:E7–E12, 2000.

74. Munzel T, Sayegh H, Freeman BA, et al: Evidence for enhanced vascular superoxide anion production in nitrate tolerance: A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 95:187–194, 1995.

75. Gori T, Parker JD: The puzzle of nitrate tolerance: Pieces smaller than we thought? Circulation 106:2404–2408, 2002.

76. Gori T, Parker JD: Nitrate tolerance: A unifying hypothesis. Circulation 106:2510–2513, 2002.

77. Yusuf S, Dagenais G, Pogue J, et al: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. N Engl J Med 342:154–160, 2000.

78. Abou-Mohamed G, Kaesemeyer WH, Caldwell RB, et al: Role of L-arginine in the vascular actions and development of tolerance to nitroglycerin. Br J Pharmacol 130:211–218, 2000.

79. Parker JO, Parker JD, Caldwell RW, et al: The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. J Am Coll Cardiol 39:1199–1203, 2002.

80. Zanzinger J: Role of nitric oxide in the neural control of cardiovascular function. Cardiovasc Res 43:639–649, 1999.

81. Death AK, Nakhla S, McGrath KC, et al: Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages. J Am Coll Cardiol 39:1943–1950, 2002.

82. Nakamura Y, Moss AJ, Brown MW, et al: Long-term nitrate use may be deleterious in ischemic heart disease: A study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J 138:577–585, 1999.

83. Heberden W: Some accounts of a disorder of the breast. Med Trans Coll Physicians (London) 2:59–62, 1772.

84. Stern S, Tzivoni D: Early detection of silent ischaemic heart disease by 24-hour electrocardiographic monitoring of active subjects. Br Heart J 36:481–486, 1974.

85. Schang SJ Jr, Pepine CJ: Transient asymptomatic S-T segment depression during daily activity. Am J Cardiol 39:396–402, 1977.

86. Herrick JB: Certain clinical features of sudden obstruction of the coronary arteries. Trans Assoc Am Physicians 27:100, 1912.

87. Kannel WB: Unrecognized myocardial infarction. In Stern S (ed): Silent Myocardial Ischemia. London, Martin Dunitz, 1998, pp 47–53.

88. Falcone C, Sconocchia R, Guasti L, et al: Dental pain threshold and angina pectoris in patients with coronary artery disease. J Am Coll Cardiol 12:348–352, 1988.

89. Stern S: Angina pectoris without chest pain. Circulation 106:1906–1908, 2002.

90. Mazzone A, Cusa C, Mazzucchelli I, et al: Increased production of inflammatory cytokines in patients with silent myocardial ischemia. J Am Coll Cardiol 38:1895–1901, 2001.

91. Pierdomenico SD, Bucci A, Costantini F, et al: Circadian blood pressure changes and myocardial ischemia in hypertensive patients with coronary artery disease. J Am Coll Cardiol 31:1627–1634, 1998.

92. Laukkanen JA, Kurl S, Lakka TA, et al: Exercise-induced silent myocardial ischemia and coronary morbidity and mortality in middle-aged men. J Am Coll Cardiol 38:72–79, 2001.

93. Panza JA: Myocardial ischemia and the pains of the heart. N Engl J Med 346:1934–1935, 2002.

94. Panting JR, Gatehouse PD, Yang G-Z, et al: Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 346:1948–1953, 2002.

95. Opie LH: Myocardial reperfusion: New ischemic syndromes. In Opie LH (ed): The Heart, Physiology from Cell to Circulation, 3rd ed. Philadelphia, Lippincott-Raven, 1988, pp 563–588.

96. Kloner RA, Jennings RB: Consequences of brief ischemia: Stunning, preconditioning, and their clinical implications. Part 1. Circulation 104:2981–2989, 2001.

1999

97. Heyndrickx GR, Millard RW, McRitchie RJ, et al: Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest 56:978–985, 1975.

98. Bolli R, Marban E: Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 79:609–634, 1999.

99. Opie LH: Reperfusion injury and its pharmacologic modification. Circulation 80:1049–1062, 1989.

100. Brooks WW, Conrad CH, Morgan JP: Reperfusion induced arrhythmias following ischaemia in intact rat heart: Role of intracellular calcium. Cardiovasc Res 29:536–542, 1995.

101. Gao WD, Altar D, Backx PH, Marban E: Relationship between intracellular calcium and contractile force in stunned myocardium. Direct evidence for decreased myofilament Ca²⁺ responsiveness and altered diastolic function in intact ventricular muscle. Circ Res 76:1036–1048, 1995.

102. Meissner A, Morgan JP: Contractile dysfunction and abnormal Ca²⁺ modulation during postischemic reperfusion in rat heart. Am J Physiol Heart Circ Physiol 268:H100–H111, 1995.

103. Rahimtoola SH: The hibernating myocardium. Am Heart J 117:211–221, 1989.

104. Beller GA: Noninvasive assessment of myocardial viability. N Engl J Med 343:1488–1490, 2000.

105. Kim RJ, Wu E, Rafael A, et al: The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343:1445–1453, 2000.

106. Shen YT, Vatner SF: Mechanism of impaired myocardial function during progressive coronary stenosis in conscious pig. Hibernation versus stunning? Circ Res 76:479–488, 1995.

107. Kim S-J, Peppas A, Hong S-K, et al: Persistent stunning induces myocardial hibernation and protection. Flow/function and metabolic mechanisms. Circ Res 92:1233–1239, 2003.

108. Afridi I, Grayburn PA, Panza JA, et al: Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction. J Am Coll Cardiol 32:921–926, 1998.

109. Senior R, Kaul S, Lahiri A: Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure. J Am Coll Cardiol 33:1848–1854, 1999.

110. Kalra DK, Zhu X, Ramchandani MK, et al: Increased myocardial gene expression of tumor necrosis factor-α and nitric oxide synthase-2. Circulation 105:1537–1540, 2002.

111. Vanoverschelde JL, Wijns W, Depre C, et al: Mechanisms of chronic regional postischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium. Circulation 87:1513–1523, 1993.

112. Vanoverschelde JL, Wijns W, Borgers M, et al: Chronic myocardial hibernation in humans. From bedside to bench. Circulation 95:1961–1971, 1997.

113. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74:1124–1136, 1986.

114. Speechly-Dick ME, Grover GJ, Yellon DM: Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K⁺ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res 77:1030–1035, 1995.

115. Bolli R: The last phase of preconditioning. Circ Res 87:972–983, 2000.

116. Sato T, Sasaki N, Seharaseyon J, et al: Selective pharmacological agents implicate mitochondrial but not sarcolemmal K_atp channels in ischemic cardioprotection. Circulation 101:2418–2423, 2000.

117. Yellon DM, Dana A: The preconditioning phenomenon: A tool for the scientist or a clinical reality? Circ Res 87:543–550, 2000.

118. Ottani F, Galvani M, Ferrini D, et al: Prodromal angina limits infarct size: A role for ischemic preconditioning. Circulation 91:291–297, 1995.

119. Ishihara M, Sato H, Tateishi H, et al: Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: Acute angiographic findings and long-term prognosis. J Am Coll Cardiol 30:970–975, 1997.

120. Todd MM: Editorial view. Anesthetic preconditioning: Serendipity and science. Anesthesiology 97:1–3, 2002.

121. Zaugg M, Lucchinetti E, Spahn DR, et al: Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K_atp channels via multiple signaling pathways. Anesthesiology 97:4–14, 2002.

122. Zaugg M, Lucchinetti E, Spahn DR, et al: Differential effects of anesthetics on mitochondrial K_atp channel activity and cardiomyocyte protection. Anesthesiology 97:15–23, 2002.

123. De Hert SG, ten Broecke PW, Mertens E, et al: Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. Anesthesiology 97:42–49, 2002.

124. Julier K, da Silva R, Garcia C, et al: Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: A double-blinded, placebo-controlled, multicenter study. Anesthesiology 98:1315–1327, 2003.

125. Otto CM, Kuusisto J, Reichenbach DD, et al: Characterization of the early lesion of "degenerative" valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90:844–853, 1994.

126. Wilmshurst PT, Stevenson RN, Griffiths H, Lord JR: A case-control investigation of the relation between hyperlipidaemia and calcific aortic valve stenosis. Heart 78:475–479, 1997.

127. Carabello BA: Clinical practice. Aortic stenosis. N Engl J Med 346:677–682, 2002.

128. Carabello BA: Evaluation and management of patients with aortic stenosis. Circulation 105:1746–1750, 2002.

129. Otto CM, Burwash IG, Legget ME, et al: Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 95:2262–2270, 1997.

130. Gorlin R, Gorlin SG: Hydraulic formula for calculation of the area of the stenotic mitral valve, other cardiac valves, and central circulatory shunts. I. Am Heart J 41:1–29, 1951.

131. Connolly HM, Oh JK, Schaff HV, et al: Severe aortic stenosis with low transvalvular gradient and severe left ventricular dysfunction: Result of aortic valve replacement in 52 patients. Circulation 101:1940–1946, 2000.

132. Khot UN, Novaro GM, Popovic AB, et al: Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 348:1756–1763, 2003.

133. Zile MR, Gaasch WH: Heart failure in aortic stenosis—improving diagnosis and treatment. N Engl J Med 348:1735–1736, 2003.

134. Braunwald E, Lambrew CT, Rickoff SD, et al: Idiopathic hypertrophic subaortic stenosis: I. A description of the disease based upon an analysis of 64 patients. Circulation 30:3–119, 1964.

135. Braunwald E, Seidman CE, Sigwart U: Contemporary evaluation and management of hypertrophic cardiomyopathy. Circulation 106:1312–1316, 2002.

136. Ommen SR, Tajik J: Hypertrophic cardiomyopathy. From bedside to bench ... and now back again? Circulation 104:126–127, 2001.

137. Nagueh SF, Bachinski LL, Meyer D, et al: Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 104:128–130, 2001.

138. Spirito P, Chiarella F, Carratino L, et al: Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 320:749–755, 1989.

139. Spirito P, Bellone P, Harris KM, et al: Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342:1777–1785, 2000.

140. Elliott PM, Gimeno Blanes JR, Mahon NG, et al: Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 357:420–424, 2001.

141. Krajcer Z, Leachman RD, Cooley DA, Coronado R: Septal myotomy-myomectomy versus mitral valve replacement in hypertrophic cardiomyopathy. Ten-year follow-up in 185 patients. Circulation 80:I57, 1989.

2000

142. Borer JS: Aortic valve replacement for the asymptomatic patient with aortic regurgitation: A new piece of the strategic puzzle. Circulation 106:2637–2639, 2002.

143. Schoen FJ, St. John Sutton M: Contemporary pathologic considerations in valvular disease. In Virmani R, Atkinson JB, Feuoglio JJ (eds): Cardiovascular Pathology. Philadelphia, WB Saunders, 1991, p 334.

144. Wells FC, Shapiro LM (eds): Mitral Valve Disease, 2nd ed. London, Butterworths, 1996.

145. Ford LE, Feldman T, Carrol JD: Valve resistance. Circulation 89:893–895, 1994.

146. Carabello BA, Crawford FA: Therapy for mitral stenosis comes full circle. N Engl J Med 331:1014–1015, 1994.

147. Reid JVO: Mid-systolic clicks. S A Med J 29:353–355, 1961.

148. Barlow JB, Pocock WA, Marchand P, Denny M: The significance of late systolic murmurs. Am Heart J 66:443–452, 1963.

149. Pellerin D, Brecker S, Veyrat C: Degenerative mitral valve disease with emphasis on mitral valve prolapse. Heart 88:iv20–iv28, 2002.

150. Fontana ME, Pence HL, Leighton RF, Wooley CF: The varying clinical spectrum of the systolic click-late systolic murmur syndrome. Circulation 41:807–816, 1970.